Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

11-12 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
30/10/26	SEK 0.3545	-5.59%	1,960,034
29/10/26	SEK 0.3755	+1.08%	4,133,745
28/10/26	SEK 0.3715	-3.88%	2,567,496
27/10/26	SEK 0.3865	-7.20%	4,130,881
26/10/26	SEK 0.4165	-1.65%	1,119,099

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Evolution of Analysts' Estimates - EPS - Alzinova AB

Revisions to estimates

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Alzinova AB

Company calendar

Market Closed - Nasdaq Stockholm 15:30:00 30/10/2026 +03			5-day change	1st Jan Change
0.3545 ^SEK	-5.59%		-16.29%	-57.24%

10-21	Alzinova Finalizes US Trial Sites for Mid-stage Alzheimer's Disease Vaccine Study	MT
10-21	Alzinova selects seven U.S. trial sites ahead of phase IIa study	FW

Market Cap	112M 11.4M 10.21M 9.4M 8.51M 15.91M 1.08B 16.21M 44.98M 570M 42.8M 41.89M 1.8B	P/E 2026 *	-2.53x	P/E 2027 *	-1.31x
Enterprise Value	103M 10.49M 9.39M 8.64M 7.83M 14.63M 996M 14.91M 41.36M 524M 39.36M 38.53M 1.65B	EV / Sales 2026 *	3.29x	EV / Sales 2027 *	-
Free-Float	82.68%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	ALZ	Delayed
Deutsche Boerse AG	78D	Delayed
Börse Stuttgart	78D	Delayed
CBOE		Real-time
CBOE		Real-time

10-21	Alzinova Finalizes US Trial Sites for Mid-stage Alzheimer's Disease Vaccine Study	MT
10-21	Alzinova selects seven U.S. trial sites ahead of phase IIa study	FW
10-21	Alzinova AB Finalises Selection Of Seven US Clinical Sites As ADVANCE Phase 2a Study Moves Toward First Participant Enrolment	CI
10-20	Alzinova carries out directed issue worth SEK 3.6m to Mangold	FW
10-15	Calendar Thursday October 15	FW
10-08	Alzinova AB Presents Latest Developments In ALZ-101 And Blood-Based Diagnostics At Redeye Neurology Day	CI
10-08	Redeye reiterates fair value of SEK 0.90 for Alzinova following rights issue	FW
10-08	Alzinova's rights issue subscribed to 86.2 percent, raises SEK 44m	FW
10-07	RX Securities reiterates Buy on Alzinova, cuts fair value to SEK 2.50	FW
10-07	Alzinova Announces Preliminary Outcome Of The Rights Issue	RE
10-07	Alzinova's rights issue subscribed to just over 80 percent	FW
10-02	Alzinova Broadens Shareholder Base With New Investor	RE
10-02	Alzinova's main shareholder sells shares for SEK6.5m, subscribes to its pro rata portion of the offering	FW

Alzinova AB Stock

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news: Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Price Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

10-08	Alzinova: Rights issue subscribed to 86.2%	AQ
10-08	Alzinova to present latest developments in ALZ-101 and blood-based diagnostics at Redeye Neurology Day	AQ
10-08	Alzinova: Rights issue completed	AQ
10-07	Alzinova announces final outcome of the rights issue	AQ
10-06	Alzinova announces preliminary outcome of the rights issue	AQ

1 day	-5.59%
1 week	-16.29%
Current month	-15.39%
1 month	-15.39%
3 months	-65.11%
6 months	-19.89%
Current year	-57.24%

1 week	0.34	0.42
1 month	0.34	0.49
Current year	0.34	1.61
1 year	0.34	2.07
3 years	0.34	4.62
5 years	0.34	7.74
10 years	0.34	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	01/10/2024
Anders Sandberg COO	Chief Operating Officer	54	17/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	27/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	01/09/2015
Anders Waas BRD	Director/Board Member	69	01/01/2018
Carol Routledge BRD	Director/Board Member	65	01/01/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	-5.59%	-16.29%	-76.40%	-85.65%	11.4M
WUXI APPTEC CO., LTD.	-0.62%	-1.87%	+46.31%	+56.99%	63.77B
ARGENX SE	+0.35%	+3.20%	+14.92%	+84.55%	56.37B
LONZA GROUP AG	+0.53%	+1.96%	+15.37%	+106.81%	54.62B
IQVIA HOLDINGS INC.	-2.81%	-4.31%	+23.50%	+50.90%	44.06B
BEONE MEDICINES AG	-0.33%	-1.93%	+20.15%	+98.45%	42.11B
REVOLUTION MEDICINES, INC.	+0.55%	+2.31%	+224.97%	+942.56%	41B
GENMAB A/S	+3.27%	+47.96%	+112.67%	+96.48%	34.92B
CELLTRION, INC.	+1.22%	-1.44%	+14.89%	+47.15%	32.82B
INSMED INCORPORATED	+0.89%	+20.55%	-42.03%	+373.03%	24.7B
Average	-0.25%	+5.16%	+35.43%	+177.13%	39.44B
Weighted average by Cap.	+0.18%	+5.44%	+48.50%	+186.12%

	2026 *	2027 *
Net sales	31.35M 3.19M 2.86M 2.63M 2.38M 4.45M 303M 4.54M 12.58M 159M 11.98M 11.72M 503M	-
Net income	1.55M 158K 141K 130K 118K 220K 14.98M 224K 622K 7.88M 592K 580K 24.85M	-84M -8.55M -7.66M -7.04M -6.38M -11.93M -812M -12.15M -33.72M -427M -32.09M -31.41M -1.35B
Net Debt	-9M -916K -820K -755K -684K -1.28M -86.99M -1.3M -3.61M -45.76M -3.44M -3.36M -144M	-4M -407K -365K -335K -304K -568K -38.66M -579K -1.61M -20.34M -1.53M -1.5M -64.13M